Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

Annals of Surgery

Volumn 246, Issue 5, 2007, Pages 780-785

  Le Roux, Carel W ^a   Welbourn, Richard ^b   Werling, Malin ^c   Osborne, Alan ^b   Kokkinos, Alexander ^a   Laurenius, Anna ^c   Lönroth, Hans ^c   Fändriks, Lars ^c   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a   Olbers, Torsten ^c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MUSGROVE PARK HOSPITAL   (United Kingdom)

^c Sahlgrenska Sjukhuset   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY;

ADULT; APPETITE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; FOOD INTAKE; HORMONE INHIBITION; HORMONE RESPONSE; HUMAN; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH BYPASS; WEIGHT REDUCTION;

APPETITE REGULATION; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; PEPTIDE YY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 35649021752     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3180caa3e3     Document Type: Article

References (31)

1. Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-114.
2. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.
3. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-350.
4. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070-1077.
5. Adrian TE, Savage AP, Fuessl HS, et al. Release of peptide YY (PYY) after resection of small bowel, colon, or pancreas in man. Surgery. 1987;101:715-719.
6. Adrian TE, Savage AP, Bacarese-Hamilton AJ, et al. Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology. 1986;90:379-384.
7. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941-948.
8. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418(6898):650-654.
9. Halatchev IG, Ellacott KL, Fan W, et al. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology. 2004;145:2585-2590.
10. Challis BG, Coll AP, Yeo GS, et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY3-36. Proc Natl Acad Sci U S A. 2004;101:4695-4700.
11. Cox JE, Randich A. Enhancement of feeding suppression by PYY(3-36) in rats with area postrema ablations. Peptides. 2004;25:985-989.
12. Riediger T, Bothe C, Becskei C, et al. Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology. 2004;79:317-326.
13. Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord. 2004;28:963-971.
14. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology. 2005;146:879-888.
15. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300-1304.
16. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999;23:304-311.
17. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.
18. Naslund E, Melin I, Gryback P, et al. Reduced food intake after jejunoileal bypass: a possible association with prolonged gastric emptying and altered gut hormone patterns. Am J Clin Nutr. 1997;66:26-32.
19. Kenler HA, Brolin RE, Cody RP. Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr. 1990;52:87-92.
20. Delgado-Aros S, Cremonini F, Castillo JE, et al. Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology. 2004;126:432-440.
21. Le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006;147:3-8.
22. Christou NV, Look D, Maclean LD. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg. 2006;244:734-740.
23. Higa KD, Ho T, Boone KB. Laparoscopic Roux-en-Y gastric bypass: technique and 3-year follow-up. J Laparoendosc Adv Surg Tech A. 2001;11:377-382.
24. McCarty TM, Arnold DT, Lamont JP, et al. Optimizing outcomes in bariatric surgery: outpatient laparoscopic gastric bypass. Ann Surg. 2005;242:494-498.
25. Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet. 2003;362(9399):1921-1928.
26. Savage AP, Adrian TE, Carolan G, et al. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut. 1987;28:166-170.
27. Adrian TE, Bloom SR, Bryant MG, et al. Distribution and release of human pancreatic polypeptide. Gut. 1976;17:940-944.
28. Patterson M, Murphy KG, Le Roux CW, et al. Characterization of ghrelin-like immunoreactivity in human plasma. J Clin Endocrinol Metab. 2005;90:2205-2211.
29. Borg CM, Le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210-215.
30. Dixon AF, Dixon JB, O'Brien PE. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab. 2005;90:813-819.
31. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 2005;146:5120-5127.